Synthesis of a novel conformationally restricted Val-Phe dipeptidomimetic

Journal of Peptide Science

Volumn 12, Issue 2, 2006, Pages 140-146

  Gilleron, Pauline ^a   Millet, Régis ^a   Domarkas, Juozas ^a   Farce, Amaury ^a   Houssin, Raymond ^a   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Building block; Pyridoisoquinoline; Val Phe peptidomimetic

Indexed keywords

1,3,4,6,7,11BETA HEXAHYDRO 4 OXO 3 PHTHALIMIDOPYRIDO[2,1ALPHA]ISOQUINOLINE 6 CARBOXYLIC ACID; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

DIPEPTIDES; MODELS, MOLECULAR; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHENYLALANINE; PROTEIN CONFORMATION; VALINE;

EID: 32544453984     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.688     Document Type: Article

References (23)

1. Hanessian S, McNaughton-Smith G, Lombart H-G, Lubell WD. Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics. Tetrahedron 1997; 53: 12 789-12 854.
2. Kee KS, Jois SD. Design of β-turn based therapeutic agents. Curr. Pharm. Des. 2003; 9: 1209-1224.
3. Sawyer TK. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin. Investig. Drugs 2004; 13: 1-19.
4. Koivunen E, Ranta TM, Annila A, Taube S, Uppala A, Jokinen M, van Willigen G, Ihanus E, Gahmberg CG. Inhibition of beta(2) integrin-mediated leucocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J. Cell Biol. 2001; 153: 905-916.
5. Lamar J, Hu J, Bueno AB, Yang H-C, Guo D, Copp JD, McGee J, Gitter B, Timm D, May P, McCarthy J, Chen S-H. Phe-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg. Med. Chem. Lett. 2004; 14: 239-243.
6. Massa SM, Xie Y, Longo FM. Alzheimer's therapeutics: neurotrophin domain small molecule mimetics. J. Mol. Neurosci. 2003; 20: 323-326.
7. Houssin R, Pommery J, Salaün M-C, Deweer S, Goossens J-F, Chavatte P, Hénichart J-P. Design, synthesis, and pharmacological evaluation of new farnesyl protein transferase inhibitors. J. Med. Chem. 2002; 45: 533-536.
8. Millet R, Domarkas J, Houssin R, Gilleron P, Goossens J-F, Chavatte P, Logé C, Pommery N, Pommery J, Hénichart J-P. Potent and selective farnesyltransferase inhibitors. J. Med. Chem. 2004; 47: 6812-6820.
9. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990; 62: 81-88.
10. Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM. Non-farnesylated tetrapeptide inhibitors of protein farnesyltransferase. J. Biol. Chem. 1991; 266: 15 575-15 578.
11. Chopineau M, Martinat N, Galet C, Guillou F, Combarnous Y. Beta-subunit 102-104 residues are crucial to confer FSH activity to equine LH/CG but are not sufficient to confer FSH activity to human CG. J. Endocrinol. 2001; 169: 55-63.
12. Jung G, Ueno H, Hayashi R, Liao TH. Identification of the catalytic histidine residue participating in the charge-relay system of carboxypeptidase Y. Protein Sci. 1995; 4: 2433-2435.
13. Collinsova M, Castro C, Garrow TA, Yiotakis A, Dive V, Jiracek J. Combining combinatorial chemistry and affinity chromatography: highly selective inhibitors of human betaine: homocysteine S-methyltransferase. Chem. Biol. 2003; 10: 113-122.
14. Robl JA, Cimarusti MP, Simpkins LM, Weller HN, Pan YY, Malley M, DiMarco JD. Peptidomimetic synthesis: a novel, highly stereoselective route to substituted Freidinger lactams. J. Am. Chem. Soc. 1994; 116: 2348-2355.
15. Plieninger H. Eine synthese der δ-oxy-α-amino-valeriansaüre und ihre Überführung in Prolin. Chem. Ber. 1950; 83: 271-272.
16. Rubottom GM, Gruber JM, Marrero R, Juve HD, Kim CW. Oxidation of alkyl trimethylsilyl ketene acetals with lead (IV) carboxylates. J. Org. Chem. 1983; 48: 4940-4944.
17. Wolff JJ, Frenking G, Harms K. The conformational behaviour of 10-substituted spiro[4.5]decanes. Chem. Ber. 1991; 124: 551-561.
18. Liu W, Xu DD, Repic O, Blacklock TJ. A mild method for ring-opening aminolysis of lactones. Tetrahedron Lett. 2001; 42: 2439-2441.
19. Speckamp WN, Moolenaar MJ. New developments in the chemistry of N-acyliminium ions and related intermediates. Tetrahedron 2000; 56: 3817-3856.
20. Maryanoff BE, Zhang H-C, Cohen JH, Turchi IJ, Maryanoff CA. Cyclisations of N-acyliminium ions. Chem. Rev. 2004; 104: 1431-1628.
21. SYBYL 6.91. Tripos Associates: St. Louis.
22. Weiner SJ, Kollman PA, Nguyen DT, Case DA. An all atom force field for simulations of proteins and nucleic acids. J. Comput. Chem. 1986; 7: 230-252.
23. Wang J, Cieplak P, Kollman P. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000; 21: 1049-1074.